12:00 AM
May 04, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GI-5005: Interim Phase II data

Interim data from 117 treatment-naïve patients in an open-label Phase II trial showed that GI-5005 plus pegylated interferon and ribavirin non-significantly improved EVR to HCV RNA <25 IU/mL at week 12 vs. pegylated interferon and ribavirin alone (94% vs. 87%, p=0.23). EVR rates...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >